Trials to date have focused on weight and metabolic outcomes, with lean mass reduction typically reported as a secondary endpoint and without standardized functional measures
[7] [8] Patients with uncontrolled or symptomatic arrhythmias, particularly atrial fibrillation with rapid ventricular response or ventricular arrhythmias, should have these conditions optimized before starting tirzepatide
In REDEFINE 1, which enrolled 3,400 adults without diabetes but with at least one weight-related condition, CagriSema led to an average weight loss of 20.4% at Week 68 , compared to 14.9% with semaglutide, 11.5% with cagrilintide, and 3% with placebo
Additionally, real-time PCR was employed to assess the expression of lineage-specific markers: RUNX-2 and ALP for osteogenesis, and FABP4 and PPAR for adipogenesis